Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
| ▸ | GNPAT | O15228 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1666636 | 1.00 | CPB2 (0.36) | CPB2CPB1GNPATCYP3A4SLC7A5 | |
| SCHEMBL1331492 | 1.00 | CPB2 (0.36) | CPB2CPB1GNPATCYP3A4SLC7A5 | |
| SCHEMBL3501671 | 0.90 | CPB2 (0.34) | CPB2CPB1 | |
| SCHEMBL8526486 | 0.88 | CPB2 (0.34) | CPB2CPB1 | |
| SCHEMBL8526485 | 0.88 | CPB2 (0.34) | CPB2CPB1 | |
| SCHEMBL13267780 | 0.87 | — | — | |
| SCHEMBL3378642 | 0.85 | CPB2 (0.34) | CPB2CPB1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30634622 | 0.85 | CPB2 (0.34) | CPB2CPB1SMN1; SMN2 | |
| SCHEMBL3378638 | 0.85 | CPB2 (0.34) | CPB2CPB1SMN1; SMN2 | |
| SCHEMBL669445 | 0.85 | CPB2 (0.34) | CPB2CPB1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248037-A1 | FLAVOUR ADDITIVES | MARS, INCORPORATED (US) | 2023-08-10 | — | — | US | claimed |
| CN-100374153-C | Use of GLP-1 or analogs in treatment of myocardial infraction | LILLY CO ELI (US) | 2008-03-12 | — | — | CN | claimed |
| CN-101005857-A | Polypeptide protracting tags | NOVO NORDISK AS (DK) | 2007-07-25 | — | — | CN | claimed |
| CN-1268391-C | Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity | LILLY CO ELI (US) | 2006-08-09 | — | — | CN | claimed |
| EP-1664108-A1 | SEPARATION OF POLYPEPTIDES COMPRISING A RACEMIZED AMINO ACID | NOVO NORDISK A/S (DK) | 2006-06-07 | — | — | EP | claimed |
| WO-2005019261-A1 | SEPARATION OF POLYPEPTIDES COMPRISING A RACEMIZED AMINO ACID | NOVO NORDISK A/S (DK) | 2005-03-03 | — | — | WO | claimed |
| EP-1355942-A2 | GLP-1 FUSION PROTEINS | ELI LILLY AND COMPANY (US) | 2003-10-29 | — | — | EP | claimed |
| WO-2002046227-A2 | GLP-1 FUSION PROTEINS | ELI LILLY AND COMPANY (US) | 2002-06-13 | — | — | WO | claimed |
| CN-117820232-A | Non-covalent dimer cations, salts thereof, preparation method thereof and antioxidation application thereof | 苏州质子链生物技术有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-115103719-A | Encapsulated fragrance based on natural amino acids | 西姆莱斯股份公司 | 2022-09-23 | — | — | CN | disclosed |
| EP-4007493-A1 | STABLE AQUEOUS MICROBIAL COMPOSITION | Biowish Technologies, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| WO-2021022128-A1 | STABLE AQUEOUS MICROBIAL COMPOSITION | BiOWiSH Technologies, Inc. (US) | 2021-02-04 | — | — | WO | disclosed |
| EP-3033112-A1 | GLP-1 DERIVATIVES, AND USES THEREOF | Novo Nordisk A/S (DK) | 2016-06-22 | — | — | EP | disclosed |
| EP-3016975-A1 | DERIVATIVES OF GLP-1 LIKE PEPTIDES, AND USES THEREOF | Novo Nordisk A/S (DK) | 2016-05-11 | — | — | EP | disclosed |
| EP-1287147-A2 | IMMUNOTOXIN FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001087982-A2 | IMMUNOTOXIN FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-11-22 | — | — | WO | disclosed |
| CN-1322137-A | Use of GLP-1 or analogs in the treatment of stroke | LILLY CO ELI (US) | 2001-11-14 | — | — | CN | disclosed |
| CN-1281369-A | Glucagon-like peptide-1 crystals | LILLY CO ELI (US) | 2001-01-24 | — | — | CN | disclosed |
| CN-1242707-A | Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity | LILLY CO ELI (US) | 2000-01-26 | — | — | CN | disclosed |
| CN-1235553-A | Use of GLP-1 or analogs in treatment of myocardial infraction | LILLY CO ELI (US) | 1999-11-17 | — | — | CN | disclosed |